Sumitovant Biopharma Ltd. didn’t just hit the ground running when it launched as a subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (DSP) at the end of 2019, and as the parent company for five companies acquired for $3bn from Roivant Sciences Inc. – it never broke its stride, since the portfolio was seamlessly integrated into DSP after the deal closed, according to Sumitovant CEO Myrtle Potter.
Potter noted that “oftentimes, two organizations come together … and it takes companies two or three years to go through...








